BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

This is the second approval for BRUKINSA in Canada, following its initial approval in March 2021 for adult patients with Waldenstrms macroglobulinemia (WM).